Research Article
Critical aspects of the Bayesian approach to phase I cancer trials
Abstract
The Bayesian approach to finding the maximum‐tolerated dose in phase I cancer trials is discussed. The suggested approach relies on a realistic dose–toxicity model, allows one to include prior information, and supports clinical decision making by presenting within‐trial information in a transparent way. The modeling and decision‐making components are flexible enough to be extendable to more complex settings. Critical aspects are emphasized and a comparison with the continual reassessment method (CRM) is performed with data from an actual trial and a simulation study. The comparison revealed similar operating characteristics while avoiding some of the difficulties encountered in the actual trial when applying the CRM. Copyright © 2008 John Wiley & Sons, Ltd.
Citing Literature
Number of times cited according to CrossRef: 132
- Daniel S-W Tan, Natasha B Leighl, Gregory J Riely, James C-H Yang, Lecia V Sequist, Juergen Wolf, Takashi Seto, Enriqueta Felip, Santiago P Aix, Maud Jonnaert, Chun Pan, Eugene Y Tan, Jinnie Ko, Susan E Moody, Dong-Wan Kim, Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study, The Lancet Respiratory Medicine, 10.1016/S2213-2600(19)30267-X, (2020).
- Shuang Li, Xian-Jin Xie, Daniel F. Heitjan, Flexible, rule-based dose escalation: The cohort-sequence design, Contemporary Clinical Trials Communications, 10.1016/j.conctc.2020.100541, (100541), (2020).
- Ruitao Lin, J. Jack Lee, Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials, Computational and Methodological Statistics and Biostatistics, 10.1007/978-3-030-42196-0_17, (395-426), (2020).
- Rachael Liu, Jianchang Lin, Pin Li, Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy, Contemporary Clinical Trials, 10.1016/j.cct.2020.106083, 96, (106083), (2020).
- Séan M. O’Cathail, Steven Davis, Jane Holmes, Richard Brown, Kerry Fisher, Leonard Seymour, Richard Adams, James Good, David Sebag-Montefiore, Tim Maughan, Maria A. Hawkins, A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR), Radiation Oncology, 10.1186/s13014-020-01593-5, 15, 1, (2020).
- Haiyan Zheng, Lisa V. Hampson, A Bayesian decision‐theoretic approach to incorporate preclinical information into phase I oncology trials, Biometrical Journal, 10.1002/bimj.201900161, 62, 6, (1408-1427), (2020).
- Apostolia M. Tsimberidou, Peter Müller, Yuan Ji, Innovative trial design in precision oncology, Seminars in Cancer Biology, 10.1016/j.semcancer.2020.09.006, (2020).
- Jean-Pierre Delord, Guillem Argilés, Jerôme Fayette, Lori Wirth, Stefan Kasper, Salvatore Siena, Ricard Mesia, Rossana Berardi, Andrés Cervantes, Jeroen Dekervel, Sylvia Zhao, Yongjian Sun, Huai-Xiang Hao, Ralph Tiedt, Sergio Vicente, Andrea Myers, Lillian L. Siu, A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment, Investigational New Drugs, 10.1007/s10637-020-00928-z, (2020).
- Sun Young Yum, What is the optimal fit-for-purpose design in an oncology first-in-human trial?: 3+3 vs. Bayesian Logistic Regression Model, Translational and Clinical Pharmacology, 10.12793/tcp.2020.28.e1, 28, (2020).
- Johann de Bono, Chia-Chi Lin, Li-Tzong Chen, Jesus Corral, Vasiliki Michalarea, Karim Rihawi, Michael Ong, Jih-Hsiang Lee, Chih-Hung Hsu, James Chih-Hsin Yang, Her-Shyong Shiah, Chia-Jui Yen, Alan Anthoney, Maria Jove, Susanne Buschke, René Fuertig, Ulrike Schmid, Rainer-Georg Goeldner, Natalja Strelkowa, Dennis Chin-Lun Huang, Thomas Bogenrieder, Chris Twelves, Ann-Lii Cheng, Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours, British Journal of Cancer, 10.1038/s41416-020-0774-1, (2020).
- Yanhong Zhou, Ruobing Li, Fangrong Yan, J. Jack Lee, Ying Yuan, A comparative study of Bayesian optimal interval (BOIN) design with interval 3 + 3 (i3 + 3) design for phase I oncology dose-finding trials, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1811147, (1-21), (2020).
- Xiang Li, Anastasia Ivanova, Hong Tian, Pilar Lim, Kevin Liu, Continual reassessment method with regularization in phase I clinical trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2020.1818251, (1-15), (2020).
- Pavel Mozgunov, Thomas Jaki, Improving safety of the continual reassessment method via a modified allocation rule, Statistics in Medicine, 10.1002/sim.8450, 39, 7, (906-922), (2019).
- Yung‐Jue Bang, Wu‐Chou Su, Martin Schuler, Do‐Hyun Nam, Wan Teck Lim, Todd M. Bauer, Analia Azaro, Ronnie Tung Ping Poon, David Hong, Chia‐Chi Lin, Mikhail Akimov, Samson Ghebremariam, Sylvia Zhao, Monica Giovannini, Brigette Ma, Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts, Cancer Science, 10.1111/cas.14254, 111, 2, (536-547), (2019).
- Ian Wadsworth, Lisa V. Hampson, Thomas Jaki, Graeme J. Sills, Anthony G. Marson, Richard Appleton, A quantitative framework to inform extrapolation decisions in children, Journal of the Royal Statistical Society: Series A (Statistics in Society), 10.1111/rssa.12532, 183, 2, (515-534), (2019).
- Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Model-Based Designs Considering Toxicity Alone, Dose-Finding Designs for Early-Phase Cancer Clinical Trials, 10.1007/978-4-431-55585-8_3, (33-79), (2019).
- Bernard North, Hemant Mahendrakumar Kocher, Peter Sasieni, A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method, BMC Cancer, 10.1186/s12885-019-5801-3, 19, 1, (2019).
- Li Liu, Lei Gao, Glen Laird, Bayesian Dose Escalation Study Design with Consideration of Both Early and Late Onset Toxicity, Contemporary Biostatistics with Biopharmaceutical Applications, 10.1007/978-3-030-15310-6_12, (225-238), (2019).
- Timothy P. Hughes, Michael J. Mauro, Jorge E. Cortes, Hironobu Minami, Delphine Rea, Daniel J. DeAngelo, Massimo Breccia, Yeow-Tee Goh, Moshe Talpaz, Andreas Hochhaus, Philipp le Coutre, Oliver Ottmann, Michael C. Heinrich, Juan L. Steegmann, Michael W.N. Deininger, Jeroen J.W.M. Janssen, Francois-Xavier Mahon, Yosuke Minami, David Yeung, David M. Ross, Martin S. Tallman, Jae H. Park, Brian J. Druker, David Hynds, Yuyan Duan, Christophe Meille, Florence Hourcade-Potelleret, K. Gary Vanasse, Fabian Lang, Dong-Wook Kim, Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure, New England Journal of Medicine, 10.1056/NEJMoa1902328, 381, 24, (2315-2326), (2019).
- Enriqueta Felip, Filippo G. de Braud, Michela Maur, Herbert H. Loong, Alice Tsang Shaw, Johan F. Vansteenkiste, Thomas John, Geoffrey Liu, Martijn P. Lolkema, Giovanni Selvaggi, Vanessa Giannone, Pilar Cazorla, Jason Baum, O. Alejandro Balbin, Luojun (Victor) Wang, Yvonne Y. Lau, Jeffrey W. Scott, Daniel Shao-Weng Tan, Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study, Journal of Thoracic Oncology, 10.1016/j.jtho.2019.10.006, (2019).
- Chi Kin Lam, Ruitao Lin, Guosheng Yin, Non‐parametric overdose control for dose finding in drug combination trials, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12349, 68, 4, (1111-1130), (2019).
- Markus Abt, Theo Dinklo, Andreas Rothfuss, Elisabeth Husar, Robert Dannecker, Katja Kallivroussis, Richard Peck, Lucette Doessegger, Christoph Wandel, A Framework Proposal to Follow‐Up on Preclinical Convulsive Signals of a New Molecular Entity in First‐in‐Human Studies Using Electroencephalographic Monitoring, Clinical Pharmacology & Therapeutics, 10.1002/cpt.1455, 106, 5, (968-980), (2019).
- Graham M. Wheeler, Adrian P. Mander, Alun Bedding, Kristian Brock, Victoria Cornelius, Andrew P. Grieve, Thomas Jaki, Sharon B. Love, Lang’o Odondi, Christopher J. Weir, Christina Yap, Simon J. Bond, How to design a dose-finding study using the continual reassessment method, BMC Medical Research Methodology, 10.1186/s12874-018-0638-z, 19, 1, (2019).
- M. Antónia Amaral Turkman, Carlos Daniel Paulino, Peter Müller, , Computational Bayesian Statistics, 10.1017/9781108646185, (2019).
- Taito Esaki, Fumihiko Hirai, Akitaka Makiyama, Takashi Seto, Hideaki Bando, Yoichi Naito, Kiyotaka Yoh, Kae Ishihara, Tomoyuki Kakizume, Kazuto Natsume, Andrea Myers, Toshihiko Doi, Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors, Cancer Science, 10.1111/cas.13956, 110, 4, (1340-1351), (2019).
- Heinz Schmidli, Bayesian Reduced Rank Regression for Classification, Applications in Statistical Computing, 10.1007/978-3-030-25147-5_2, (19-30), (2019).
- Ying Yuan, J. Jack Lee, Susan G. Hilsenbeck, Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority, JCO Precision Oncology, 10.1200/PO.19.00032, 3, (1-12), (2019).
- Haiyan Zheng, Lisa V Hampson, Simon Wandel, A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials, Statistical Methods in Medical Research, 10.1177/0962280218820040, (096228021882004), (2019).
- Weijia Zhang, Xikui Wang, Po Yang, A new design of the continual reassessment method, Communications in Statistics - Simulation and Computation, 10.1080/03610918.2019.1592191, (1-10), (2019).
- Marc S. Raab, Sheeba K. Thomas, Enrique M. Ocio, Andreas Guenther, Yeow-Tee Goh, Moshe Talpaz, Nicolas Hohmann, Sylvia Zhao, Fang Xiang, Carl Simon, K. Gary Vanasse, Shaji K. Kumar, The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma, Leukemia, 10.1038/s41375-019-0482-0, (2019).
- Nolan A. Wages, Evan Bagley, Evaluation of irrational dose assignment definitions using the continual reassessment method, Clinical Trials, 10.1177/1740774519873316, (174077451987331), (2019).
- Puntipa Wanitjirattikal, Chenyang Shi, A Bayesian zero-inflated binomial regression and its application in dose-finding study, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2019.1684313, (1-12), (2019).
- Johanna C. Bendell, Helge G. Bischoff, Jimmy Hwang, Hans Christian Reinhardt, Thomas Zander, Xuejing Wang, Scott Hynes, Celine Pitou, Robert Campbell, Philip Iversen, Daphne L. Farrington, Katherine Bell-McGuinn, Michael Thomas, A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer, Investigational New Drugs, 10.1007/s10637-019-00873-6, (2019).
- C. Mayer, I. Perevoskaya, S. Leonov, V. Dragalin, Y. Pritchett, A. Bedding, A. Hartford, P. Fardipour, G. Cicconetti, Simulation Practices For Adaptive Trial Designs In Drug And Device Development, Statistics in Biopharmaceutical Research, 10.1080/19466315.2018.1560359, (1-20), (2019).
- James J. Harding, Todd M. Bauer, Daniel S. W. Tan, Philippe L. Bedard, Jordi Rodon, Toshihiko Doi, Christian Schnell, Varsha Iyer, Fabienne Baffert, Rajkumar Radhakrishnan, Claire Fabre, Dejan Juric, Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor, Investigational New Drugs, 10.1007/s10637-018-0627-4, 37, 2, (271-281), (2018).
- Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E. Krop, Howard Burris, Angel Guerrero-Zotano, Carolyn D. Britten, Carlos Becerra, Jan Schellens, Donald A. Richards, Martin Schuler, Maysa Abu-Khalaf, Faye M. Johnson, Malcolm Ranson, Jeff Edenfield, Antonio P. Silva, Wolfgang Hackl, Cornelia Quadt, David Demanse, Vincent Duval, Jose Baselga, Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer, Cancer Chemotherapy and Pharmacology, 10.1007/s00280-018-3610-z, 82, 2, (285-298), (2018).
- Ben Tran, Richard D. Carvajal, Aurelien Marabelle, Sandip Pravin Patel, Patricia M. LoRusso, Erik Rasmussen, Gloria Juan, Vijay V. Upreti, Courtney Beers, Gataree Ngarmchamnanrith, Patrick Schöffski, Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors, Journal for ImmunoTherapy of Cancer, 10.1186/s40425-018-0407-x, 6, 1, (2018).
- Heng Zhou, Thomas A. Murray, Haitao Pan, Ying Yuan, Comparative review of novel model‐assisted designs for phase I clinical trials, Statistics in Medicine, 10.1002/sim.7674, 37, 14, (2208-2222), (2018).
- Elizabeth Krachey, Kert Viele, Philip C. Spinella, Marie E. Steiner, Nicole D. Zantek, Roger J. Lewis, The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients, Journal of Trauma and Acute Care Surgery, 10.1097/TA.0000000000001876, 84, (S41-S46), (2018).
- Jordi Rodon, Giuseppe Curigliano, Jean-Pierre Delord, Wael Harb, Analia Azaro, Yu Han, Celine Wilke, Valerie Donnet, Dalila Sellami, Thaddeus Beck, A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors, Oncotarget, 10.18632/oncotarget.25854, 9, 60, (31709-31718), (2018).
- Ruitao Lin, Guosheng Yin, Uniformly most powerful Bayesian interval design for phase I dose‐finding trials, Pharmaceutical Statistics, 10.1002/pst.1889, 17, 6, (710-724), (2018).
- Amy Cotterill, Thomas Jaki, Dose‐escalation strategies which use subgroup information, Pharmaceutical Statistics, 10.1002/pst.1860, 17, 5, (414-436), (2018).
- Book Reviews, Journal of the American Statistical Association, 10.1080/01621459.2018.1486071, 113, 522, (948-953), (2018).
- Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M Voorhees, Brandi Reeves, Edward N Libby, Paul G Richardson, Larry D Anderson, Heather J Sutherland, Kwee Yong, Axel Hoos, Michele M Gorczyca, Soumi Lahiri, Zangdong He, Daren J Austin, Joanna B Opalinska, Adam D Cohen, Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial, The Lancet Oncology, 10.1016/S1470-2045(18)30576-X, (2018).
- Dejan Juric, Jordi Rodon, Josep Tabernero, Filip Janku, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schuler, Marta Gil-Martin, Hope S. Rugo, Ruth Seggewiss-Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga, Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA -Altered Solid Tumors: Results From the First-in-Human Study , Journal of Clinical Oncology, 10.1200/JCO.2017.72.7107, 36, 13, (1291-1299), (2018).
- Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F. Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S.W. Tan, Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR -Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer , Journal of Clinical Oncology, 10.1200/JCO.2018.77.7326, 36, 31, (3101-3109), (2018).
- Yukio Kobayashi, Wataru Munakata, Michinori Ogura, Toshiki Uchida, Masafumi Taniwaki, Tsutomu Kobayashi, Fumika Shimada, Masataka Yonemura, Fumiko Matsuoka, Takeshi Tajima, Kimikazu Yakushijin, Hironobu Minami, Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia, International Journal of Hematology, 10.1007/s12185-017-2327-9, 107, 1, (83-91), (2017).
- Toshihiko Doi, Becker Hewes, Tomoyuki Kakizume, Takeshi Tajima, Norifumi Ishikawa, Yasuhide Yamada, Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors, Cancer Science, 10.1111/cas.13428, 109, 1, (193-198), (2017).
- Philippe L. Bédard, Michael A. Davies, Scott Kopetz, Dejan Juric, Geoffrey I. Shapiro, Jason J. Luke, Anna Spreafico, Bin Wu, Christelle Castell, Corinne Gomez, Sylvaine Cartot‐Cotton, Florent Mazuir, Michel Dubar, Sandrine Micallef, Brigitte Demers, Keith T. Flaherty, First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors, Cancer, 10.1002/cncr.31044, 124, 2, (315-324), (2017).
- Sharon B Love, Sarah Brown, Christopher J Weir, Chris Harbron, Christina Yap, Birgit Gaschler-Markefski, James Matcham, Louise Caffrey, Christopher McKevitt, Sally Clive, Charlie Craddock, James Spicer, Victoria Cornelius, Embracing model-based designs for dose-finding trials, British Journal of Cancer, 10.1038/bjc.2017.186, 117, 3, (332-339), (2017).
- Toshihiko Doi, Kohei Shitara, Yoichi Naito, Akihiko Shimomura, Yasuhiro Fujiwara, Kan Yonemori, Chikako Shimizu, Tatsunori Shimoi, Yasutoshi Kuboki, Nobuaki Matsubara, Atsuko Kitano, Takahiro Jikoh, Caleb Lee, Yoshihiko Fujisaki, Yusuke Ogitani, Antoine Yver, Kenji Tamura, Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study, The Lancet Oncology, 10.1016/S1470-2045(17)30604-6, 18, 11, (1512-1522), (2017).
- Shinsuke Iida, Kenshi Suzuki, Shigeru Kusumoto, Masaki Ri, Nobuhiro Tsukada, Yu Abe, Masayuki Aoki, Mitsuo Inagaki, Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study, International Journal of Hematology, 10.1007/s12185-017-2281-6, 106, 4, (541-551), (2017).
- John F Seymour, Shuo Ma, Danielle M Brander, Michael Y Choi, Jacqueline Barrientos, Matthew S Davids, Mary Ann Anderson, Anne W Beaven, Steven T Rosen, Constantine S Tam, Betty Prine, Suresh K Agarwal, Wijith Munasinghe, Ming Zhu, L Leanne Lash, Monali Desai, Elisa Cerri, Maria Verdugo, Su Young Kim, Rod A Humerickhouse, Gary B Gordon, Thomas J Kipps, Andrew W Roberts, Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study, The Lancet Oncology, 10.1016/S1470-2045(17)30012-8, 18, 2, (230-240), (2017).
- Mark W Kieran, Julia Chisholm, Michela Casanova, Alba A Brandes, Isabelle Aerts, Eric Bouffet, Simon Bailey, Sarah Leary, Tobey J MacDonald, Francoise Mechinaud, Kenneth J Cohen, Riccardo Riccardi, Warren Mason, Darren Hargrave, Stacey Kalambakas, Priya Deshpande, Feng Tai, Eunju Hurh, Birgit Geoerger, Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma, Neuro-Oncology, 10.1093/neuonc/nox109, 19, 11, (1542-1552), (2017).
- Cody Chiuzan, Jonathan Shtaynberger, Gulam A. Manji, Jimmy K. Duong, Gary K. Schwartz, Anastasia Ivanova, Shing M. Lee, Dose-finding designs for trials of molecularly targeted agents and immunotherapies, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1289952, 27, 3, (477-494), (2017).
- P. Colin, M. Delattre, P. Minini, S. Micallef, An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1295248, 27, 6, (1054-1072), (2017).
- Kerry Lynn Reynolds, Philippe L. Bedard, Se-Hoon Lee, Chia-Chi Lin, Josep Tabernero, Maria Alsina, Ezra Cohen, José Baselga, George Blumenschein, Donna M. Graham, Ignacio Garrido-Laguna, Dejan Juric, Sunil Sharma, Ravi Salgia, Abdelkader Seroutou, Xianbin Tian, Rose Fernandez, Alex Morozov, Qing Sheng, Thiruvamoor Ramkumar, Angela Zubel, Yung-Jue Bang, A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer, BMC Cancer, 10.1186/s12885-017-3641-6, 17, 1, (2017).
- Graham M. Wheeler, Michael J. Sweeting, Adrian P. Mander, Toxicity‐dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials, Statistics in Medicine, 10.1002/sim.7280, 36, 16, (2499-2513), (2017).
- Sheila M. Bird, Rosemary A. Bailey, Andrew P. Grieve, Stephen Senn, Statistical issues in first‐in‐human studies on BIA 10‐2474: Neglected comparison of protocol against practice, Pharmaceutical Statistics, 10.1002/pst.1801, 16, 2, (100-106), (2017).
- Benjamin Izar, William Sharfman, F. Stephen Hodi, Donald Lawrence, Keith T. Flaherty, Ravi Amaravadi, Kevin B. Kim, Igor Puzanov, Jeffrey Sosman, Reinhard Dummer, Simone M. Goldinger, Lyhping Lam, Shefali Kakar, Zhongwen Tang, Oliver Krieter, David F. McDermott, Michael B. Atkins, A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status, Cancer Medicine, 10.1002/cam4.1140, 6, 8, (1904-1914), (2017).
- Lucas Moreno, Andrew D. J. Pearson, Xavier Paoletti, Irene Jimenez, Birgit Geoerger, Pamela R. Kearns, C. Michel Zwaan, Francois Doz, Andre Baruchel, Josef Vormoor, Michela Casanova, Stefan M. Pfister, Bruce Morland, Gilles Vassal, Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective, Nature Reviews Clinical Oncology, 10.1038/nrclinonc.2017.59, 14, 8, (497-507), (2017).
- Kristen M Cunanan, Joseph S Koopmeiners, Hierarchical models for sharing information across populations in phase I dose-escalation studies, Statistical Methods in Medical Research, 10.1177/0962280217703812, (096228021770381), (2017).
- Bo Huang, Paul Bycott, Enayet Talukder, Novel dose-finding designs and considerations on practical implementations in oncology clinical trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2016.1148715, 27, 1, (44-55), (2016).
- Shunji Takahashi, Takayuki Kobayashi, Junichi Tomomatsu, Yoshinori Ito, Hisanobu Oda, Tatsuhiro Kajitani, Tomoyuki Kakizume, Takeshi Tajima, Hiromi Takeuchi, Heiko Maacke, Taito Esaki, LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer, Cancer Chemotherapy and Pharmacology, 10.1007/s00280-016-3214-4, 79, 1, (131-138), (2016).
- Andrew P. Grieve, Response‐adaptive clinical trials: case studies in the medical literature, Pharmaceutical Statistics, 10.1002/pst.1778, 16, 1, (64-86), (2016).
- Hironobu Minami, Yuichi Ando, Brigette Buig Yue Ma, Jih‐ Hsiang Lee, Hiroyuki Momota, Yutaka Fujiwara, Leung Li, Koichi Fukino, Koji Ito, Takeshi Tajima, Asuka Mori, Chia‐Chi Lin, Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors, Cancer Science, 10.1111/cas.13022, 107, 10, (1477-1483), (2016).
- Anthony Kong, Daniel Rea, Samreen Ahmed, J. Thaddeus Beck, Rafael López López, Laura Biganzoli, Anne C. Armstrong, Massimo Aglietta, Emilio Alba, Mario Campone, Shu-Fang Hsu Schmitz, Caroline Lefebvre, Mikhail Akimov, Soo-Chin Lee, Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen, Oncotarget, 10.18632/oncotarget.8974, 7, 25, (37680-37692), (2016).
- Alexia Iasonos, Nolan A. Wages, Mark R. Conaway, Ken Cheung, Ying Yuan, John O'Quigley, Dimension of model parameter space and operating characteristics in adaptive dose‐finding studies, Statistics in Medicine, 10.1002/sim.6966, 35, 21, (3760-3775), (2016).
- Adelaide Doussau, Birgit Geoerger, Irene Jiménez, Xavier Paoletti, Innovations for phase I dose-finding designs in pediatric oncology clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2016.01.009, 47, (217-227), (2016).
- K. Watanabe, S. Otsu, Y. Hirashima, R. Morinaga, K. Nishikawa, Y. Hisamatsu, T. Shimokata, M. Inada-Inoue, T. Shibata, H. Takeuchi, T. Watanabe, K. Tokushige, H. Maacke, K. Shiaro, Y. Ando, A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, 10.1007/s00280-016-3019-5, 77, 6, (1157-1164), (2016).
- Karen Sinclair, Els Kinable, Kai Grosch, Jixian Wang, Modelling PK/QT relationships from Phase I dose‐escalation trials for drug combinations and developing quantitative risk assessments of clinically relevant QT prolongations, Pharmaceutical Statistics, 10.1002/pst.1747, 15, 3, (264-276), (2016).
- Yong-Mi Kim, Dursun Delen, Medical informatics research trend analysis: A text mining approach, Health Informatics Journal, 10.1177/1460458216678443, (146045821667844), (2016).
- Wei Zheng, Yang Zhao, Yuefeng Lu, Harry Miao, Hengchang Liu, A Bayesian three-parameter logistic model for early- and late-onset DLTs in oncology Phase I studies, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.1003433, 26, 2, (339-351), (2015).
- Beat Neuenschwander, Simon Wandel, Satrajit Roychoudhury, Stuart Bailey, Robust exchangeability designs for early phase clinical trials with multiple strata, Pharmaceutical Statistics, 10.1002/pst.1730, 15, 2, (123-134), (2015).
- Xavier Paoletti, Adélaïde Doussau, Monia Ezzalfani, Elisa Rizzo, Rodolphe Thiébaut, Dose finding with longitudinal data: simpler models, richer outcomes, Statistics in Medicine, 10.1002/sim.6552, 34, 22, (2983-2998), (2015).
- Adrian P. Mander, Michael J. Sweeting, A product of independent beta probabilities dose escalation design for dual‐agent phase I trials, Statistics in Medicine, 10.1002/sim.6434, 34, 8, (1261-1276), (2015).
- Kyriakos P. Papadopoulos, Randi Isaacs, Sanela Bilic, Kerstin Kentsch, Heather A. Huet, Matthias Hofmann, Drew Rasco, Nicole Kundamal, Zhongwhen Tang, Jennifer Cooksey, Amit Mahipal, Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor, Cancer Chemotherapy and Pharmacology, 10.1007/s00280-015-2712-0, 75, 5, (887-895), (2015).
- Jürgen Hummel, Song Wang, John Kirkpatrick, Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials, Clinical Investigation, 10.4155/cli.15.14, 5, 4, (401-413), (2015).
- Makoto Nishio, Haruyasu Murakami, Atsushi Horiike, Toshiaki Takahashi, Fumihiko Hirai, Naoko Suenaga, Takeshi Tajima, Kota Tokushige, Masami Ishii, Anthony Boral, Matthew Robson, Takashi Seto, Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors, Journal of Thoracic Oncology, 10.1097/JTO.0000000000000566, 10, 7, (1058-1066), (2015).
- Zhengjia Chen, Ying Yuan, Zheng Li, Michael Kutner, Taofeek Owonikoko, Walter J. Curran, Fadlo Khuri, Jeanne Kowalski, Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2015.05.014, 43, (133-141), (2015).
- Amand F. Schmidt, Irene Klugkist, Olaf H. Klungel, Mirjam Nielen, Anthonius de Boer, Arno W. Hoes, Rolf H.H. Groenwold, Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs, Journal of Clinical Epidemiology, 10.1016/j.jclinepi.2014.11.015, 68, 4, (387-396), (2015).
- Pierre Colin, Sandrine Micallef, Maud Delattre, Pierre Mancini, Eric Parent, Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology, Statistics in Medicine, 10.1002/sim.6548, 34, 22, (2999-3016), (2015).
- Amy Cotterill, Daniel Lorand, Jixian Wang, Thomas Jaki, A practical design for a dual‐agent dose‐escalation trial that incorporates pharmacokinetic data, Statistics in Medicine, 10.1002/sim.6482, 34, 13, (2138-2164), (2015).
- Suyu Liu, Haitao Pan, Jielai Xia, Qin Huang, Ying Yuan, Bridging continual reassessment method for phase I clinical trials in different ethnic populations, Statistics in Medicine, 10.1002/sim.6442, 34, 10, (1681-1694), (2015).
- Wai Yin Yeung, John Whitehead, Bruno Reigner, Ulrich Beyer, Cheikh Diack, Thomas Jaki, Bayesian adaptive dose‐escalation procedures for binary and continuous responses utilizing a gain function, Pharmaceutical Statistics, 10.1002/pst.1706, 14, 6, (479-487), (2015).
- Alexia Iasonos, Mithat Gönen, George J. Bosl, Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?, Journal of Clinical Oncology, 10.1200/JCO.2014.59.8466, 33, 19, (2221-2225), (2015).
- M.‐K. Riviere, F. Dubois, S. Zohar, Competing designs for drug combination in phase I dose‐finding clinical trials, Statistics in Medicine, 10.1002/sim.6094, 34, 1, (1-12), (2014).
- Xiaobin Yang, Keying Ye, Yanping Wang, A study of the probit model with latent variables in Phase I clinical trials, Journal of Statistical Computation and Simulation, 10.1080/00949655.2014.885976, 85, 8, (1621-1633), (2014).
- Björn Bornkamp, Practical considerations for using functional uniform prior distributions for dose‐response estimation in clinical trials, Biometrical Journal, 10.1002/bimj.201300138, 56, 6, (947-962), (2014).
- Inna Perevozskaya, Lixin Han, Kristen Pierce, Continual Reassessment Method for a First-in-Human Trial: From Design to Trial Implementation, Practical Considerations for Adaptive Trial Design and Implementation, 10.1007/978-1-4939-1100-4_19, (357-381), (2014).
- David Lawrence, Frank Bretz, Approaches for Optimal Dose Selection for Adaptive Design Trials, Practical Considerations for Adaptive Trial Design and Implementation, 10.1007/978-1-4939-1100-4_7, (125-137), (2014).
- Xavier Paoletti, Adélaide Doussau, Dose Finding Methods in Oncology: From the Maximum Tolerated Dose to the Recommended Phase II Dose, Developments in Statistical Evaluation of Clinical Trials, 10.1007/978-3-642-55345-5, (335-361), (2014).
- Christy Chuang-Stein, Frank Bretz, The Need for and the Future of Adaptive Designs in Clinical Development, Practical Considerations for Adaptive Trial Design and Implementation, 10.1007/978-1-4939-1100-4_1, (3-23), (2014).
- Alexia Iasonos, John O'Quigley, Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials, Journal of Clinical Oncology, 10.1200/JCO.2013.54.6051, 32, 23, (2505-2511), (2014).
- Aaron R. Hansen, Donna M. Graham, Gregory R. Pond, Lillian L. Siu, Phase 1 Trial Design: Is 3 + 3 the Best?, Cancer Control, 10.1177/107327481402100304, 21, 3, (200-208), (2014).
- Jeffrey R. Infante, E. Claire Dees, Anthony J. Olszanski, Shyeilla V. Dhuria, Suman Sen, Scott Cameron, Roger B. Cohen, Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors, Journal of Clinical Oncology, 10.1200/JCO.2013.52.3993, 32, 28, (3103-3110), (2014).
- Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin J. Solomon, Juergen Wolf, Michael Thomas, Martin Schuler, Geoffrey Liu, Armando Santoro, Yvonne Y. Lau, Meredith Goldwasser, Anthony L. Boral, Jeffrey A. Engelman, Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer , New England Journal of Medicine, 10.1056/NEJMoa1311107, 370, 13, (1189-1197), (2014).
- Toshihiko Doi, Yusuke Onozawa, Nozomu Fuse, Takayuki Yoshino, Kentaro Yamazaki, Junichiro Watanabe, Mikhail Akimov, Matthew Robson, Narikazu Boku, Atsushi Ohtsu, Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, 10.1007/s00280-014-2521-x, 74, 3, (629-636), (2014).
- Yuichi Ando, Megumi Inada‐Inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Toshihiko Doi, Phase I dose‐escalation study of buparlisib (BKM120), an oral pan‐class I PI3K inhibitor, in Japanese patients with advanced solid tumors, Cancer Science, 10.1111/cas.12350, 105, 3, (347-353), (2014).
- José Pinheiro, Björn Bornkamp, Ekkehard Glimm, Frank Bretz, Model‐based dose finding under model uncertainty using general parametric models, Statistics in Medicine, 10.1002/sim.6052, 33, 10, (1646-1661), (2013).
- See more
